Kluytmans-Vandenbergh M F Q, Kluytmans J A J W, Voss A
Laboratory for Microbiology and Infection Control, Amphia Hospital, location Molengracht, 90158, 4800 RK Breda, The Netherlands.
Infection. 2005 Oct;33(5-6):309-13. doi: 10.1007/s15010-005-5079-z.
Hospitals are faced with the increasingly rapid emergence and dissemination of antimicrobial-resistant microorganisms. US and European guidelines on the prevention of antimicrobial resistance in hospitals were, until recently, mainly directed at methicillin-resistant Staphylococcus aureus (MRSA). In 2004, the Dutch Working Party on Infection Prevention issued a guideline on the prevention of nosocomial transmission of highly resistant microorganisms (HRMO), in order to fulfill the growing need for additional guidance on the control of other pathogens with acquired resistance and the potential to spread within hospitals (such as glycopeptide-resistant Enterococcus faecium, penicillin-resistant Streptococcus pneumoniae, extendedspectrum beta-lactamase producing Enterobacteriaceae, and other (multi)drug-resistant gram-negatives). In addition to providing criteria for defining HRMO, the Dutch guideline provides recommendations on isolation of patients, active surveillance, and contact tracing. The guideline will enable the comparison of HRMO rates between hospitals, and may be used to evaluate the efficacy of programs to control antibiotic use and/or nosocomial transmission of resistant pathogens. The eventual success of nationwide implementation of this guideline remains to be established in the coming years.
医院面临着抗菌药物耐药微生物日益迅速的出现和传播。直到最近,美国和欧洲关于医院抗菌药物耐药性预防的指南主要针对耐甲氧西林金黄色葡萄球菌(MRSA)。2004年,荷兰感染预防工作小组发布了一项关于预防高耐药性微生物(HRMO)医院内传播的指南,以满足对控制其他获得性耐药病原体以及在医院内传播潜力的病原体(如耐糖肽粪肠球菌、耐青霉素肺炎链球菌、产超广谱β-内酰胺酶肠杆菌科细菌以及其他(多重)耐药革兰氏阴性菌)控制的更多指导的日益增长的需求。除了提供定义HRMO的标准外,荷兰指南还提供了关于患者隔离、主动监测和接触者追踪的建议。该指南将使医院之间能够比较HRMO发生率,并可用于评估控制抗生素使用和/或耐药病原体医院内传播计划的效果。该指南在全国范围内实施的最终成功仍有待在未来几年确定。